Skip to content

Association Between CRSA and OSA

The Association Between Central Serous Chorioretinopathy and the Obstructive Sleep Apnea

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04634786
Acronym
CRSA
Enrollment
70
Registered
2020-11-18
Start date
2021-02-06
Completion date
2021-08-06
Last updated
2021-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chorioretinopathy, Obstructive Sleep Apnea

Brief summary

This goal of this study is to know the association between the central serous chorioretinopathy and the obstructive sleep apnea. Many studies have been done in order to assess the association between the central serous chorioretinopathy and obstructive sleep apnea and the results are always controverses actually.

Interventions

None listed

Sponsors

Poitiers University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Central serous chorioretinopathy since 6 months at least * Patients beyond 18 years old

Exclusion criteria

\- All retina pathology will be excluded : diabetes with affected retina, maculopathy, retina central veinous oclusion, epithéliopathy

Design outcomes

Primary

MeasureTime frameDescription
Association between central serous chorioretinopathy and the obstructive sleep apnea.During 3 months we will collect the results of Berlin survey.Percentage of high risks of obstructive sleep apnea in patients affected by central serous chorioretinopathy in using the Berlin survey. The Berlin questions include 3 categories: The category 1 is positive if 2 answers are positive. The category 2 is positive if 2 answers are positive. The category 3 is positive if 1 answer is positive. Finally, if 2 categories are positive, the patient is considered as high risk of obstructive sleep apnea.

Countries

France

Contacts

Primary ContactNicolas LEVEZIEL, Pr
nicolas.leveziel@chu-poitiers.fr0549444182

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026